GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invites Biocore Co Ltd (XKRX:216400) » Definitions » EBIT

Invites Biocore Co (XKRX:216400) EBIT : ₩-4,966 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Invites Biocore Co EBIT?

Invites Biocore Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was ₩-4,966 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-4,966 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Invites Biocore Co's annualized ROC % for the quarter that ended in Dec. 2023 was -5.18%. Invites Biocore Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -85.36%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Invites Biocore Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -7.23%.

Invites Biocore Co EBIT Historical Data

The historical data trend for Invites Biocore Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invites Biocore Co EBIT Chart

Invites Biocore Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only 1,455.77 2,398.57 3,572.34 1,190.49 -4,965.65

Invites Biocore Co Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only 1,455.77 2,398.57 3,572.34 1,190.49 -4,965.65

Competitive Comparison of Invites Biocore Co's EBIT

For the Biotechnology subindustry, Invites Biocore Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invites Biocore Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invites Biocore Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Invites Biocore Co's EV-to-EBIT falls into.


Invites Biocore Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-4,966 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invites Biocore Co  (XKRX:216400) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Invites Biocore Co's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-5348.321 * ( 1 - 11.4% )/( (59892.35 + 123146.08)/ 2 )
=-4738.612406/91519.215
=-5.18 %

where

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=85505.136 - 5632.994 - ( 43454.818 - max(0, 35864.958 - 55844.75+43454.818))
=59892.35

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=114081.41 - 10597.266 - ( 8565.927 - max(0, 58634.612 - 38972.676+8565.927))
=123146.08

Note: The Operating Income data used here is one times the annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Invites Biocore Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-4965.647/( ( (6938.968 + max(-8136.726, 0)) + (4695.342 + max(-5092.275, 0)) )/ 2 )
=-4965.647/( ( 6938.968 + 4695.342 )/ 2 )
=-4965.647/5817.155
=-85.36 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6761.76 + 1373.467 + 646.14) - (5632.994 + 0 + 11285.099)
=-8136.726

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7091.715 + 2046.047 + 16600.145) - (10597.266 + 0 + 20232.916)
=-5092.275

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Invites Biocore Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-4965.647/68685.930
=-7.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invites Biocore Co EBIT Related Terms

Thank you for viewing the detailed overview of Invites Biocore Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Invites Biocore Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invites Biocore Co Ltd (XKRX:216400) » Definitions » EBIT
Comparable Companies
XKRX:288330 XKRX:049960 XKRX:244460 XKRX:002630 XKRX:225220 XKRX:352770 XKRX:341170 XKRX:217950 XKRX:038070 XKRX:185490 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
60-21, Gasan-dong, IT Mi-Rae Tower, 9th Floor, Geumcheon-gu, Seoul, KOR
Website
http://www.bio-core.com
Invites Biocore Co Ltd, formerly Biocore Co Ltd is a biotechnology company. It experiments on biological organism for pharmaceutical companies, CRO, health care institutions and to pharmaceutical related research centers.

Invites Biocore Co Headlines

No Headlines